These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Thailand's Prime-Boost HIV Vaccine Phase III. Trinvuthipong C Science; 2004 Feb; 303(5660):954-5. PubMed ID: 14963308 [No Abstract] [Full Text] [Related]
10. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Longo O; Tripiciano A; Fiorelli V; Bellino S; Scoglio A; Collacchi B; Alvarez MJ; Francavilla V; Arancio A; Paniccia G; Lazzarin A; Tambussi G; Din CT; Visintini R; Narciso P; Antinori A; D'Offizi G; Giulianelli M; Carta M; Di Carlo A; Palamara G; Giuliani M; Laguardia ME; Monini P; Magnani M; Ensoli F; Ensoli B Vaccine; 2009 May; 27(25-26):3306-12. PubMed ID: 19208456 [TBL] [Abstract][Full Text] [Related]
11. Remune trial will stop; new trials planned. James JS AIDS Treat News; 1999 May; (No 319):1-2. PubMed ID: 11366461 [TBL] [Abstract][Full Text] [Related]
12. Update on HIV vaccines. Meldorf M; Corey L STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929 [TBL] [Abstract][Full Text] [Related]
13. Progress in development and testing of novel recombinant vaccine platforms for HIV. Weiner DB Springer Semin Immunopathol; 2006 Nov; 28(3):195-6. PubMed ID: 17043866 [No Abstract] [Full Text] [Related]
14. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
15. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. Ratto-Kim S; Sitz KV; Garner RP; Kim JH; Davis C; Aronson N; Ruiz N; Tencer K; Redfield RR; Birx DL J Infect Dis; 1999 Feb; 179(2):337-44. PubMed ID: 9878016 [TBL] [Abstract][Full Text] [Related]
16. A primer on HIV type 1-specific immune function and REMUNE. Moss RB; Giermakowska WK; Savary JR; Theofan G; Daigle AE; Richieri SP; Jensen FC; Carlo DJ AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S167-75. PubMed ID: 9672235 [TBL] [Abstract][Full Text] [Related]
17. Trial suggests vaccines could aid HIV therapy. Check E Nature; 2003 Apr; 422(6933):650. PubMed ID: 12700722 [No Abstract] [Full Text] [Related]
18. Immune enhancement trial begins. AIDS Patient Care STDS; 1996 Aug; 10(4):263. PubMed ID: 11361606 [No Abstract] [Full Text] [Related]
19. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508 [TBL] [Abstract][Full Text] [Related]